Paul Kelly has been appointed CEO of Orchid Biosciences, filling a position that has been left vacant since Dale Pfost resigned as CEO in December 2002.
Kelly comes to Orchid from software company OmniViz, where he was CEO. He was previously a co-founder and CEO of Gemini Genomics, a UK-based population genetics firm that was acquired by Sequenom in 2001.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.